Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
November 12, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched Myriad myPath™ Melanoma, a new diagnostic test to effectively...
Myriad Genetics to Present at the 2013 Credit Suisse Annual Healthcare Conference
November 08, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, Chief Financial Officer, is scheduled to present at the 2013 Credit Suisse Annual...
Myriad Genetics Reports Financial Results for First Quarter of Fiscal Year 2014
November 05, 2013 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal first quarter ended Sept. 30, 2013. Revenue for the fiscal first...
Myriad myPlan(TM) Lung Cancer Test Launched to Leading Oncologists
October 29, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with...
Myriad myPlan(TM) Lung Cancer Test Meets Primary Endpoint in Validation Study
October 28, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted...
Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study
October 24, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data this week at the American Society of Human Genetics (ASHG) annual meeting in...
Myriad Genetics to Announce Fiscal First Quarter 2014 Financial Results on Tuesday November 5, 2013
October 23, 2013 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2014 following the close of...
Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
October 14, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively...
Myriad Genetics Study Highlights Importance of myRisk(TM) Hereditary Cancer Testing
October 09, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data showing the high prevalence and overlap between hereditary colon cancer and...
Myriad's myRisk Hereditary Cancer(TM) Test Improves Colon Cancer Testing by 60 Percent
October 07, 2013 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel,...